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metabolites using a targeted metabolomics approach: results
of the EPIC-potsdam study
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BACKGROUND/OBJECTIVES: The metabolic consequences of type of body shape need further exploration. Whereas accumulation
of body mass in the abdominal area is a well-established metabolic risk factor, accumulation in the gluteofemoral area is
controversially debated. We evaluated the associations of anthropometric markers of overall body mass and body shape with 127
serum metabolites within a sub-sample of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort.
SUBJECTS/METHODS: The cross-sectional analysis was conducted in 2270 participants, randomly drawn from the EPIC-Potsdam
cohort. Metabolites were measured by targeted metabolomics. To select metabolites related with both waist circumference (WC)
(abdominal subcutaneous and visceral fat) and hip circumference (HC) (gluteofemoral fat, muscles and bone structure) correlations
(r) with body mass index (BMI) as aggregating marker of body mass (lean and fat mass) were calculated. Relations with body shape
were assessed by median metabolite concentrations across tertiles of WC and HC, mutually adjusted to each other.
RESULTS: Correlations revealed 23 metabolites related to BMI (r⩾ I0.20 I). Metabolites showing relations with BMI were showing
similar relations with HC adjusted WC (WCHC). In contrast, relations with WC adjusted HC (HCWC) were less concordant with relations
of BMI and WCHC. In both sexes, metabolites with concordant relations regarding WCHC and HCWC included tyrosine, diacyl-
phosphatidylcholine C38:3, C38:4, lyso-phosphatidylcholine C18:1, C18:2 and sphingomyelin C18:1; metabolites with opposite
relations included isoleucine, diacyl-phosphatidylcholine C42:0, acyl–alkyl-phosphatidylcholine C34:3, C42:4, C42:5, C44:4 and C44:6.
Metabolites specifically related to HCWC included acyl–alkyl-phosphatidylcholine C34:2, C36:2, C38:2 and C40:4, and were solely
observed in men. Other metabolites were related to WCHC only.
CONCLUSIONS: The study revealed specific metabolic profiles for HCWC as marker of gluteofemoral body mass differing from those
for BMI and WCHC as markers of overall body mass and abdominal fat, respectively. Thus, the study suggests that gluteofemoral
mass may have less-adverse metabolic implications than abdominal fat.
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INTRODUCTION
Overweight and obesity are related to metabolic disorders (for
example, impaired fasting glucose, impaired glucose tolerance,
hypertriglyceridemia, type-2-diabetes).1 A major determinant of
weight-associated metabolic disorders is the type of body shape.
The commonly referred ‘apple’ shape, characterized by predomi-
nating abdominal fat accumulation, is supposed to pose greater
health risks than the ‘pear’ shape, characterized by predominating
gluteofemoral fat accumulation.2 Health risks related to abdominal
fat are mainly driven by the visceral fat compartment, whose
expansion is a well-established metabolic risk factor.3,4 Expansion
of subcutaneous fat, such as gluteofemoral fat, presumably does
not have metabolically adverse effects, but is supposed to act
protective.5,6
Overweight and obesity are classified by body mass index (BMI),
a simple population level measure, which is defined as one’s
weight in kilograms divided by the square of one’s height in
meters. Consequently, BMI is an aggregating marker of body mass
covering lean mass (mainly including muscles, bones and water)
and fat mass. Using BMI to classify excess body fat is based on the
assumption that at a given height, higher weight is associated
with increased fatness.7 To assess body shape, circumferences
such as waist circumference (WC) and hip circumference (HC) are
commonly used as surrogate measures. Whereas WC comprises
mainly abdominal subcutaneous and visceral fat, HC comprises
gluteofemoral fat, muscles and bone structure (pelvic width).
Furthermore, it must be borne in mind that anthropometric
measures are generally affected by an individual’s body frame.
Even though circumferences can only provide rough estimates of
one’s true body composition, WC is supposed to be the most
effective single measure for visceral fat.8–10 HC generally reflects
gluteofemoral body mass, but it is not able to differentiate
between parts attributed to fat, muscles or bone structure.
Moreover, parts may clearly differ between men and women.
However, in both sexes HC highly correlates with subcutaneous
fat.10
Excess weight affects the whole body and apparently involves
metabolic changes.11–14 The metabolomic approach has already
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been used to identify metabolites involved in overweight and
obesity11,15–19 and weight-associated metabolic disorders, for
example, pre-diabetes (that is, impaired fasting glucose and/or
impaired glucose tolerance)12,20–23 and clinically manifest type-2-
diabetes.24–26 The metabolic state particularly related with body
shape is not fully understood. It is assumed that the accumulation
of visceral fat has an important etiological role for weight-
associated metabolic disorders,27,28 whereas the accumulation of
gluteofemoral body mass was found to be associated with more
favorable metabolic profiles, when abdominal fat was taken into
account.29,30 In the present study, we aimed to gain a broader
understanding of the metabolic state related to body mass in
general and body shape in particular. Therefore, we evaluated the
associations of anthropometric markers of overall body mass and
body shape with 127 targeted metabolites in chronic disease-free
individuals within a sub-sample of the European Prospective
Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort.
SUBJECTS AND METHODS
Ethics statement
The study was approved by the ethics committee of the Medical
Association of the State of Brandenburg. A written informed consent from
all participants was obtained.
Study population
The EPIC-Potsdam cohort is part of the ongoing multicenter EPIC study and
comprises 27 548 participants from the general population of Potsdam and
surroundings, recruited between 1994 and 1998.31
The present analysis was conducted in a randomly drawn sub-sample
(n=2500) from the EPIC-Potsdam study population with blood samples
(n=26 448). Participants, mainly aged 35–65 years, filled out socio-
demographic and lifestyle questionnaires, a validated food-frequency
questionnaire and completed an interview on medical history. Participants
additionally had anthropometric measures and a blood sample taken by
trained staff.32,33 In brief, 30 ml of blood were collected and immediately
processed according to a strict protocol.34 The blood was fractionated into
serum, plasma, buffy coat and erythrocytes, aliquoted into straws of 0.5 ml,
and stored in liquid nitrogen tanks at − 196 °C until analysis.
In this cross-sectional study we excluded participants with missing
anthropometric measurements, missing blood samples or biomarker
measurement, missing covariate information and participants with
prevalent chronic diseases. Thus, the analytical sample included 2270
individuals.
Measurement of anthropometry
Anthropometry was measured according to standardized procedures by
trained staff as described earlier.35 Weight was obtained without shoes in
light clothing to the nearest of 0.1 kg. Height and circumferences were
measured to the nearest of 0.1 cm. WC was taken midway between the
iliac crest and the lower ribs. HC was measured over the buttocks. BMI was
calculated as weight in kilograms divided by the square of height in
meters.
Measurement of serum metabolites
Metabolomic measurements were performed in the Genome Analysis
Center at the Helmholtz Center Munich by electrospray ionization-tandem
mass spectrometry using the AbsoluteIDQ p150 kit (BIOCRATES Life
Sciences AG, Innsbruck, Austria). Sample preparation has been described in
detail previously.36,37 In brief, 10 μl of serum were pipetted onto a filter in a
96-well sandwich plate, containing stable isotope-labeled internal stan-
dards. Amino acids (AA) were derivated with 5% phenylisothiocyanate
reagent. After extraction of metabolites and internal standards with 5 mM
ammonium acetate in methanol, the solution was centrifuged through a
filter membrane and diluted with mass spectrometry running solvent. Final
extracts were analyzed and 163 metabolites quantified simultaneously,
including free carnitine, 40 acylcarnitines, 14 AA (13 proteinogenic
+ornithine), one hexose (sum of six carbon monosaccharides without
distinction of isomers), 92 glycerophospholipids (15 lyso-phosphatidyl-
cholines (lysoPC), 77 diacyl (aa)- and acyl–alkyl (ae)- phosphatidylcholines
(PC)) and 15 sphingomyelins (SM). Internal standards were used to
calculate metabolite concentrations. Fatty-acid side chains were abbre-
viated Cx:y where x represented the number of carbon atoms and y the
number of double bonds. The acylcarnitines were derivates of carnitine
(C0) with one fatty-acid bond (Cx:y). The prefix ‘lyso’ indicated a single
fatty-acid side chain. Concentrations are reported in μM. The median
analytical variance of EPIC-Potsdam samples was 7.3% within-plate
coefficient of variation and 11.3% between-plates coefficient of
variation.38 After exclusion of metabolites below the limit of detection
(n=30) and those with high analytical variance in our samples (n= 6), 127
metabolites (17 acylcarnitines, 14 AA, one hexose, 81 glycerophospholipids
and 14 SM) were remaining for the present analysis.
Statistical analysis
Descriptive statistics were calculated as mean and s.d. for continuous
variables and percentage for categorical variables.
As most of the metabolite concentrations were normally distributed
they were not transformed. In order to conduct robust and coherent
analyses of all measured metabolites nonparametric statistics were chosen.
To select most body fat-relevant metabolites related with both WC (as
aggregating measure of abdominal subcutaneous and visceral fat) and HC
(as aggregating measure of gluteofemoral fat, muscles and bone
structure), associations between metabolites and BMI (as marker of excess
body fat and aggregating marker of body fat mass and lean mass) were
first evaluated by means of Spearman’s partial rank correlation coefficients
(r). Correlation analyses were adjusted for height (per cm), age (per year),
education (current in training/no certificate/skill; professional school;
collage of higher education, university), smoking (never smoker; ex-
smoker; smoker), physical activity (inactive; moderately inactive; moder-
ately active; active), alcohol consumption (0 g per day; 40–6 g per day;
46–12 g per day; 412–24 g per day; 424–60 g per day; 460–96 g
per day;496 g per day), fasting status (fasting, non-fasting) and prevalent
hypertension and were performed stratified by sex. As correlations of 127
metabolites with BMI, WC and HC showed almost identical relations with
BMI and WC, but markedly lower relations with HC (data not presented), it
appears unlikely that we missed relevant metabolites specifically related to
abdominal and/or gluteofemoral body mass by the BMI-based selection
process. Thereafter, metabolites with r⩾ I0.20 I in men and/or women were
analyzed regarding body shape. Median metabolite concentrations (95%
confidence intervals) associated with abdominal fat were assessed across
sex-specific tertiles of WC additionally adjusted for HC, whereas median
metabolite concentrations associated with gluteofemoral body mass were
assessed across sex-specific tertiles of HC additionally adjusted for WC.
These statistical models with mutual adjustment of WC and HC allowed the
investigation of metabolites related to abdominal fat mass (approximated
through differing WC and constant HC) and gluteofemoral body mass
(approximated through differing HC and constant WC). Further adjust-
ments corresponded to the adjustment set described for the correlation
analyses. The lowest tertile of metabolite concentrations were used as
reference categories. Distribution-free 95% confidence intervals were
calculated as described by Hahn and Meeker.39 The margin of I0.20 I was
chosen to focus the analyses on metabolites of most metabolic relevance
regarding abdominal and gluteofemoral body mass. This margin was
considered as sufficiently high, as above this margin clearest trends across
tertiles of abdominal and gluteofemoral body mass were observed.
All statistical analyses were carried out with SAS Enterprise Guide release
6.1 (SAS Institute, Cary, NC, USA). Statistical codes available from the
corresponding author.
RESULTS
The present study population comprised 2270 adults (63.0%
women) free of chronic diseases with a mean age of 49.7 ± 8.9
years (mean± s.d.). Baseline characteristics are presented in
Table 1. The study population was slightly overweight according
to BMI. WC was at the upper boundaries of normal in both sexes.
Out of 127 metabolites a set of 23 metabolites showed r⩾ I0.20 I
with overall body mass, measured by BMI, in men and women,
respectively (Table 2). This metabolite set included three AA
(tyrosine, valine, isoleucine), five PCaa (C38:3, C38:4, C40:5, C40:6,
C42:0), 11 PCae (C34:2, C34:3, C36:2, C38:2, C40:4, C42:3, C42:4,
C42:5, C44:4, C44:5, C44:6), three lysoPC (C17:0, C18:1, C18:2) and
one SM (C18:1). AA, the SM, and shorter-chained PCaa (⩽C40)
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were positively correlated with BMI, whereas PCae, lysoPCs and
the longer-chained PCaa (C42) were negatively correlated. There
were no differences in direction of correlations between men and
women, but strength of correlations differed between sexes.
Within the set of 23 metabolites, AA, PCaa, longer-chained PCae
(C44) and lysoPC (C18) were stronger correlated in men, whereas
the remaining PCae (⩽C42), lysoPC (C17) and the SM were
stronger correlated in women. Significantly higher r were solely
seen for tyrosine in men and PCae C38:2 in women.
The set of 23 metabolites was thereupon analyzed regarding
metabolite concentrations related to body shape. For each tertile
of WC—adjusted for HC and other variables and thus reflecting
abdominal fat—and HC—adjusted for WC and other variables and
thus reflecting gluteofemoral body mass—, the median concen-
tration of the selected metabolites was calculated. Figure 1 (men)
and Figure 2 (women) show the results of these calculations for
each metabolite illustrating the results for WC given a constant HC
(WCHC) in red and the results for HC given a constant WC (HCWC) in
blue. For the reader’s convenience the direction of the medians
across tertiles were additionally displayed by arrows below the
graphics of the metabolite results. To gain a comprehensive view,
correlations with BMI as well whether metabolites had been
already identified as being associated with pre-diabetes and/or
type-2-diabetes in previous studies are additionally indicated. We
found that median metabolite concentrations across tertiles of
WCHC often show a similar pattern as the correlation of the
metabolites with BMI. This similarity was most pronounced for
metabolites with r⩾ I0.20 I such as tyrosine, valine, isoleucine,
PCaa C38:3, C38:4, C40:5, C40:6, PCae C42:4, C44:4, lysoPC C18:1
and C18:2 in men and valine, PCaa C38:3, PCae C34:2, C34:3, C36:2,
C38:2, C40:4, C42:3, C42:4, C42:5, C44:6 and lysoPC C18:2 in
women. Metabolites with r⩾ I0.20 I and no clear trend across
tertiles of WCHC such as PCaa C42:0, PCae C34:3, C42:5, C44:5 and
C44:6 in men and lysoPC C17 in women showed at least
tendencies of concordant directions of associations, whereas
metabolites with ro I0.20 I predominantly showed not more than
tendencies across the tertiles. In contrast, median metabolite
concentrations across tertiles of HCWC were less concordant with
the results of BMI and WCHC. This is of particular interest as
associations with the analyzed metabolites were not studied
before. Some metabolites showed median metabolite concentra-
tions across tertiles of HCWC in the same direction as across tertiles
of WCHC, such as tyrosine, PCaa C38:3, C38:4, C40:5, C40:6, lysoPC
C17:0, C18:1, C18:2 and SM C18:1 in men and tyrosine, PCaa C38:3,
C38:4, lysoPC C18:1, C18:2 and SM C18:1 in women. However,
some metabolites showed opposite directions as across tertiles of
WCHC, such as isoleucine, PCaa C42:0, and PCae C34:3, C42:3,
C42:4, C42:5, C44:4, C44:6 in men and valine, isoleucine, PCaa
Table 1. Baseline characteristics of the study population
Baseline characteristics Total Men Women
(n= 2270) (n=839) (n= 1431)
Anthropometry
BMI (kg m− 2) 25.9 (4.1) 26.5 (3.4) 25.5 (4.5)
Waist circumference (cm) 85.0 (12.5) 93.4 (9.7) 80.1 (11.2)
Hip circumference (cm) 100.6 (7.9) 99.7 (6.0) 101.1 (8.8)
Education
Current in training/no
certificate/skill
36.74 31.35 39.90
Professional school 24.58 15.38 29.98
Collage of higher education,
university
38.68 53.28 30.12
Smoking status
Never smoker 47.62 29.92 58.00
Ex-smoker 31.54 43.86 24.32
Smoker 20.84 26.22 17.68
Physical activity
Inactive 19.38 18.24 20.06
Moderately inactive 39.60 38.26 40.39
Moderately active 24.01 24.91 23.48
Active 17.00 18.59 16.07
Alcohol consumption
0 g per day 2.78 2.98 2.66
40 to 6 g per day 38.85 16.33 52.06
46 to 12 g per day 20.97 15.97 23.90
412 to 24 g per day 18.11 24.79 14.19
424 to 60 g per day 16.34 32.78 6.71
460 to 96 g per day 2.47 5.84 0.49
496 g per day 0.48 1.31 —
Continuous variables are presented as means (s.d.). Categorical variables
are presented in percent. Anthropometric variables and covariates are
presented in total and separated by sex. Alcohol consumption category
496 g per day includes only men.
Table 2. Spearman’s partial rank correlation coefficients r (95% CI) of
serum metabolites with BMI, stratified by sex
Metabolites Men Women
(n= 839) (n= 1431)
Amino Acids
Tyrosine* 0.29 (0.22; 0.35) 0.12 (0.07; 0.17)
Valine 0.24 (0.17; 0.30) 0.20 (0.15; 0.25)
Isoleucine 0.22 (0.15; 0.28) 0.17 (0.12; 0.22)
Diacyl-phosphatidylcholines
PCaa C38:3* 0.34 (0.27; 0.39) 0.25 (0.20; 0.30)
PCaa C38:4 0.24 (0.17; 0.30) 0.13 (0.08; 0.18)
PCaa C40:5 0.20 (0.13; 0.27) 0.08 (0.02; 0.13)
PCaa C40:6 0.23 (0.16; 0.29) 0.11 (0.06; 0.16)
PCaa C42:0 −0.24 (−0.30; − 0.17) − 0.19 (−0.24; − 0.14)
Acyl–alkyl-phosphatidylcholines
PCae C34:2 − 0.13 (−0.20; − 0.06) −0.21 (−0.26; − 0.16)
PCae C34:3* −0.21 (−0.27; − 0.14) −0.27 (−0.31; − 0.22)
PCae C36:2* − 0.17 (−0.23; − 0.10) −0.27 (−0.32; − 0.22)
PCae C38:2* − 0.13 (−0.20; − 0.06) −0.26 (−0.31; − 0.22)
PCae C40:4 − 0.14 (−0.21; − 0.07) −0.21 (−0.26; − 0.16)
PCae C42:3 − 0.18 (−0.25; − 0.11) −0.22 (−0.27; − 0.17)
PCae C42:4* −0.24 (−0.30; − 0.17) −0.26 (−0.30; − 0.21)
PCae C42:5 −0.22 (−0.28; − 0.15) −0.21 (−0.26; − 0.16)
PCae C44:4 −0.22 (−0.28; − 0.15) − 0.18 (−0.23; − 0.13)
PCae C44:5 −0.20 (−0.27; − 0.13) − 0.16 (−0.21; − 0.10)
PCae C44:6 −0.22 (−0.28; − 0.15) −0.20 (−0.25; − 0.15)
Lyso-phosphatidylcholines
lysoPC a C17:0 − 0.16 (−0.23; − 0.10) −0.21 (−0.26; − 0.16)
lysoPC a C18:1 −0.24 (−0.30; − 0.17) − 0.17 (−0.22; − 0.12)
lysoPC a C18:2* −0.25 (−0.31; − 0.19) −0.20 (−0.25; − 0.15)
Sphingomyelins
SM C18:1 0.13 (0.06; 0.20) 0.21 (0.16; 0.26)
Abbreviations: a, acyl; aa, diacyl; ae, acyl–alkyl; BMI, body mass index;
CI, confidence interval; PC, phosphatidylcholine; SM, sphingomyelin.
Correlation coefficients are adjusted for body height, age, education,
smoking, physical activity, alcohol consumption, fasting status and prevalent
hypertension, and rounded to two decimal places. Correlation coefficients
⩾ I0.20 I are marked in bold. Metabolites with correlation coefficients ⩾ I0.25 I
in men and/or women are additionally marked by asterisks (*). Fatty-acid side
chains were abbreviated Cx:y where x represents the number of carbon
atoms and y the number of double bounds.
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C40:5, C40:6, C42:0, PCae C34:2, C34:3, C40:4, C42:4, C42:5, C44:4,
C44:5 and C44:6 in women. Moreover, some metabolites showed
clear trends across tertiles of HCWC, but not more than tendencies
across tertiles of WCHC, such as PCae C34:2, C36:2, C38:2, C40:4 in
men; and some metabolites showed clear trends across tertiles of
WCHC, but not more than tendencies across tertiles of HCWC, such
as valine and PCae C44:5 in men and PCae C36:2, C38:2, C42:3 and
lysoPC C17:0 in women. Consequently, the 23 metabolites could
be subdivided into four groups: those being related in the same
way with both measurements of body shape—the gluteofemoral
body mass and the abdominal fat mass, those being inversely
related with the measurements of body shape, and those being
specifically related with either the gluteofemoral body mass or the
abdominal fat mass. We noted that the assignment of the
metabolites to one of the four groups is also sex-specific.
DISCUSSION
We analyzed 23 serum metabolites related to body mass with
r⩾ I0.20 I at least in one sex for their relations with body mass
either located at the waist or at the hip. We observed that a body
mass deposition at the hip has unique and sometimes opposite
relations with metabolites compared with a deposition at the
waist. The deposition at the waist shows similar relations with
metabolites than overall fatness (BMI) and includes metabolites
known to be related to type-2-diabetes.
First, we like to discuss the type of metabolites being
considered as reflecting overall fatness that also includes specific
deposition particularly at the waist. We identified two branched-
chain (valine, isoleucine) and one aromatic (tyrosine) AA related to
overall fatness. These results are in line with previous findings
suggesting that both branched-chain (BCAA) and aromatic AA
were positively associated with excess body weight.16,40 Moreover,
the observed stronger correlations in men basically support the
hypothesis that males have higher rates of protein turnover than
females.16 We could further show that shorter-chained PCaa
(⩽C40) were positively correlated with overall fatness, and longer-
chained PCaa (C42) and all PCae and lysoPC were negatively
correlated. Thereby, PCaa were stronger related in men, whereas
PCae were stronger related in women. In agreement with our
findings lower PCae41,42 and lower lysoPC concentrations were
observed in obese individuals in other studies.15,17 However,
concerning lysoPC evidence is inconsistent as Pietiläinen et al.41
reported higher lysoPC concentrations related to obesity. The
present study also identified one SM (C18:1) related to overall
body mass, conforming to previous results.43
The strong similarity of findings regarding metabolites asso-
ciated with BMI and WCHC is not surprising as BMI and WC are
Figure 1. Median serum concentrations across tertiles of WC (red) and HC (blue) in relation to corresponding reference groups in men.
Reference groups are lowest tertiles of WC and HC, respectively. Tertile classifications are as follows: WC tertile 1: WCo89 cm, WC tertile 2:
89 cm⩽WCo97 cm, WC tertile 3: WC⩾97 cm; HC tertile 1: HCo97 cm, HC tertile 2: 97 cm⩽HCo 102 cm, HC tertile 3: HC⩾ 102 cm.
Adjustment sets included the following covariates: body height, age, education, smoking, physical activity, alcohol consumption, fasting
status, prevalent hypertension as well as HC for concentrations across tertiles of WC and WC for concentrations across tertiles of HC,
respectively. To gain a comprehensive view, correlation coefficients (r) with BMI are added below: r⩾ I0.20 I are marked in bold, r⩾ I0.25 I are
additionally marked by asterisk. Directions (dir) of median serum concentrations across tertiles are presented by arrows: ↑ or ↓= clear trend;
↗ or ↘ = tendency; → = marginal tendency. Metabolites already associated with pre-diabetes (Pre-D) and/or type-2-diabetes (T2D) in
previous studies are additionally marked: 1=Würtz et al.;45 2=Wang et al.;46 3= Floegel et al.;24 4=Wang-Sattler et al.21 HC, hip circumference;
WC, waist circumference.
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highly correlated. This confirms a strong positive correlation
between the underlying metabolite networks of BMI and WC
(r= 0.99) within the same data set.44 This finding is also supporting
our decision to select metabolites for further analysis based on
correlations with BMI and on the margin of I0.20 I. Above this
margin, clearest trends of median metabolite concentrations
across tertiles of abdominal and gluteofemoral body mass were
observed. Metabolites specifically related to abdominal fat were
observed for different metabolites in men (valine, PCae C44:5) and
women (PCae C36:2 C38:2, C42:3, lysoPC C17:0). Interestingly, the
two metabolites observed in men were previously identified as
risk metabolites of pre-diabetes45 and type-2-diabetes.24,46 They
might act as early indicators of adverse health implications
specifically related to abdominal fat. The exact mechanism that
explains elevated health risks associated with WC is not firmly
established. It is assumed that visceral fat has an important
etiological role of diabetes by release of free fatty acids directly
from visceral fat into hepatic circulation, resulting in insulin
resistance, hyperinsulinemia,27,28 increased gluconeogenesis and
dyslipidemia.47,48 So far, little attention has been given to
associations between type of body shape and metabolite profiles
in metabolically healthy individuals. The revealed metabolites are
possibly involved in underlying mechanisms resulting in such
disorders. Increased protein catabolism secondary to insulin
resistance has been suggested as possible explanation for
increased BCAA in obesity.49 In moderate upper body obesity
increased proteolysis and impairment of insulin’s antiproteolytic
action was found.50,51 Furthermore, tissue-specific alterations in
BCAA metabolism, in the liver and adipose tissue but not in
muscle, may contribute to increased plasma concentrations of
BCAA in obesity.49 Besides higher serum concentrations of BCAA
we found lower serum concentration of PCae and lysoPC to be
related with increased abdominal fat. Plasma phospholipids,
mostly secreted by the liver, are abundantly present in all classes
of lipoproteins. PCae were found to be inversely correlated with
plasma triglycerides.24 Furthermore, higher levels of PCae were
observed to be related with improved insulin sensitivity and
reduced insulin secretion;24 in addition, they may act antioxidative
and prevent lipoprotein oxidation.42
The novel insight relates to the body mass at the hip—mostly
reflecting subcutaneous fat, muscle mass and bone structure
(pelvic width). It seems as if increased body mass at this site has its
own metabolic consequences, probably with less-adverse implica-
tions than large overall fat volumes and abdominal fat when the
metabolites related to this deposition were taken into considera-
tion. The interpretation of metabolic consequences related to
body mass at the hip may vary between sexes. Although
gluteofemoral fat and pelvic width may be the main components
of HC in women, pelvic width and muscles may be the main
components in men. On the one hand, underlying mechanisms of
less-adverse implications may be related to subcutaneous fat,
which has lower levels of basal lipolysis and lipolytic stimulation
compared with visceral fat, potentially resulting in lower flux of
free fatty acids into the blood.47 Furthermore, it has been
suggested that subcutaneous fat may act as a sink for circulating
free fatty acids.48 Subcutaneous fat is additionally supposed to
Figure 2. Median serum concentrations across tertiles of WC (red) and HC (blue) in relation to corresponding reference groups in women.
Reference groups are lowest tertiles of WC and HC, respectively. Tertile classifications are as follows: WC tertile 1: WCo74 cm, WC tertile 2:
74 cm ⩽WCo83.5 cm, WC tertile 3:⩾ 83.5 cm; HC tertile 1: HCo97 cm, HC tertile 2: 97 cm⩽HCo103.5 cm, HC tertile 3: HC⩾ 103.5 cm.
Adjustment sets included the following covariates: body height, age, education, smoking, physical activity, alcohol consumption, fasting
status, prevalent hypertension as well as HC for concentrations across tertiles of WC and WC for concentrations across tertiles of HC,
respectively. To gain a comprehensive view, correlation coefficients (r) with BMI are added below: r⩾ I0.20 I are marked in bold, r⩾ I0.25 I are
additionally marked by asterisk. Directions (dir) of median serum concentrations across tertiles are presented by arrows: ↑ or ↓= clear trend;
↗ or ↘= tendency;→ = marginal tendency. Metabolites already associated with pre-diabetes (Pre-D) and/or type-2-diabetes (T2D) in
previous studies are additionally marked: 1=Würtz et al.;45 2=Wang et al.;46 3= Floegel et al.;24 4=Wang-Sattler et al.21 HC, hip circumference;
WC, waist circumference.
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consist of smaller adipocytes that have relatively higher insulin
sensitivity.52 Owing to differences in body fat distribution
metabolic impact of subcutaneous fat may vary between men
and women. On the other hand, less-adverse implications may be
related to muscle mass, the main target organ for insulin and one
of the sites of insulin resistance.30 A lower HC possibly indicates
relatively small gluteal and leg muscle mass. This could be more
apparent in men owing to lower gluteofemoral fat storage
compared with women. It has been shown in healthy men that
relatively small leg muscle mass is related to an elevated waist-to-
hip ratio53 and to different glucose levels between Indian and
Swedish men.54
We could note that also deposition of body mass at this site
show for some metabolites similar relations with overall and
abdominal fat. Those metabolites showing corresponding associa-
tions in men and women included tyrosine, PCaa C38:3, C38:4,
lysoPC C18:1, C18:2, and SM C18:1—with mostly clearer trends in
men. We also observed some metabolites related in men only
(PCaa C40:5, C40:6, lysoPC C17:0). Tyrosine, PCaa C38:3, C40:5 and
lysoPC C18:2 were already found to be related to pre-diabetes
and/or type-2-diabetes.21,24,45,46 Metabolites with concordant
relations with abdominal and gluteofemoral body mass might
be considered as reflecting large body volumes and include
indicators of elevated metabolic risks associated with excess body
weight in general wherever it is located. Higher levels of aromatic
AA have been related to excess body fat, insulin55 and insulin
resistance.12 Choline-containing phospholipids such as PCaa
and lysoPC represent the major components of cellular
membranes.56 Their blood concentration may be influenced by
hepatic de novo synthesis and redistribution from plasma
membranes.57 As constituents of lipoproteins, PCaa have been
related to hepatic secretion of triyglceride-rich VLDL particles and
HDL.56 The observed associations of sphingomyelin SM C18:1 with
higher abdominal and gluteofemoral body mass seem to be
attributed to both fat and muscle mass, what is in line with
previous studies.58,59
However, we also observed metabolites showing opposite
associations regarding type of body shape. In men and women,
isoleucine, PCaa C42:0, PCae C34:3, C42:4, C42:5, C44:4 and C44:6
exhibited this property—with mostly clearer trends in women. We
also observed some metabolites related in women only (valine,
PCaa C40:5, C40:6, PCae C34:2, C40:4, C44:5). Valine, isoleucine,
PCaa C40:5, PCae C34:3, C42:5, C44:4 and C44:5 were already
found to be related to pre-diabetes and/or type-2-diabetes.24,45,46
To our surprise, the direction of relations with the compartment
‘waist’ corresponded to the findings with pre-diabetes and/or
type-2-diabetes, and the relations with the compartment ‘hip’
were opposite. This finding strengthens the view that gluteofe-
moral body mass deposition might even induce metabolic
processes protecting against type-2-diabetes. In women, fat
deposition at the hip region and regional differences in adipocyte
metabolism (lipoprotein lipase activity and lipolysis) are more
pronounced than in men.60 In the present study a possible
protective role of lager hips was found to be more apparent in
women than in men. This finding suggests that metabolic
processes protecting against type-2-diabetes might be particularly
linked to subcutaneous fat deposition.
Metabolites specifically related to gluteofemoral body mass
only were solely observed in men (PCae C34:2, C36:2, C38:2, C40:4)
and comprised none of the identified risk metabolites for pre-
diabetes and/or type-2-diabetes. The present findings suggest
that gluteofemoral body mass deposition has different metabolic
consequences and support the hypothesis that increased
gluteofemoral body mass presumably goes along with less-
adverse health implications.
Among the strengths of the present study are the use of
standardized procedures for the assessment of anthropometry by
trained personnel and the availability of concentrations of
metabolites with known identity comprising different classes.
Determination by the validated AbsoluteIDQ p150 kit allowed
simultaneous quantification using a modern high-throughput
technique, which has been approved and standardized. Further
strengths of our study are the possibility to consider relevant
confounding variables and the exclusion of individuals with
chronic diseases to avoid effects of accompanying metabolic
changes. The limitations of the study refer to its cross-sectional
nature and the use of anthropometrical measurements, which are
only rough estimations of the true body composition. Measure-
ments of body composition obtained by direct methods such as
dual-energy X-ray absorptiometry, magnetic resonance imaging or
bodyscanner accurately and precisely quantify compartments of
body composition. Such methods require special and expensive
equipment and are often unsuitable to screen large samples.
Indubitably, mutual adjustment of WC and HC can only provide
an approximation of metabolite concentration differences related
to abdominal and gluteofemoral body mass, respectively.
Nevertheless, to receive hints for differences in associations
related to abdominal and gluteofemoral body mass, it seems
methodologically appropriate. A further limitation relates to the
selection of metabolites, which is highly artificial and of rather
small extent when considering what’s technically possible in
metabolomics. Furthermore, variances of metabolite concentra-
tions depend not only on biological variability, but also on the
precision of the measurements, which might have influenced our
assumption of metabolic relevance. Based on findings of a
reliability study, metabolites below the detection limit and those
with high analytical variance were excluded to ensure valid
measurements.38
In conclusion, the study confirmed several metabolite associa-
tions with BMI as anthropometric marker of overall body mass,
provided metabolic profiles concerning WCHC as marker of
abdominal fat mass and revealed specific metabolic profiles for
HCWC as marker of gluteofemoral body mass differing from those
of overall body mass and abdominal fat. Thereby, we observed
sex-specific differences. Metabolites already identified as being
associated with pre-diabetes and/or type-2-diabetes were assign-
able to the three abdominal fat-related metabolite groups and
appear independent from their associations with gluteofemoral
body mass, underscoring the lower adverse metabolic conse-
quences by this compartment. The observation of independent
associations of metabolites with gluteofemoral body mass as well
as opposite relations with abdominal and gluteofemoral body
mass even suggest that increased deposition in the gluteofemoral
area could possibly reduce the risk of type-2-diabetes owing to
beneficial metabolic impacts. Future studies using direct measure-
ments of body composition need to further validate these
findings.
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